Changeflow GovPing Government General Class 2 Recall Oxoid Agglutinating Sera Salmone...
Urgent Enforcement Amended Final

Class 2 Recall Oxoid Agglutinating Sera Salmonella 9-0 Cross-Reactivity

Favicon for changeflow.com FDA Device Recalls (Class II)
Filed
Detected
Email

Summary

Remel Europe Ltd. initiated a Class 2 medical device recall for Oxoid Agglutinating Sera, Salmonella 9-0 (R30957301) affecting 16 lots distributed in the US (117 units) and internationally (950 units). The affected lots are not performing to IFU criteria, showing cross-reactions with 2-0 within 60 seconds, which may result in misidentification of a Salmonella 9-O serotype as a 2-O serotype. Consignees were notified on March 25, 2026 via urgent medical device recall letter and are advised to review results, destroy remaining inventory, and complete the acknowledgement form for replacement or credit.

“Affected lots are not performing to IFU criteria showing cross reactions with 2-0 within 60 seconds.”

FDA , verbatim from source
Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Device Recalls (Class II) for new government general regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 79 changes logged to date.

What changed

The recall affects Oxoid Agglutinating Sera, Salmonella 9-0 (R30957301) across 16 lot codes distributed nationwide in the US (AL, CA, FL, IA, IL, IN, MI, MN, MO, NC, NE, OH, SD, TX, WA) and internationally. Affected lots are not meeting instruction-for-use criteria due to cross-reactivity with the 2-0 antigen within 60 seconds, creating a risk that Salmonella 9-O serotypes could be misidentified as 2-O serotypes.\n\nClinical laboratories using this antisera product should immediately quarantine and destroy any remaining inventory of affected lots, refrain from using the product for diagnostic testing, and contact the recalling firm at 800-2556730 to complete the acknowledgement form for replacement or credit. Laboratories that have already obtained test results using affected lots should review those results for potential misclassification.

What to do next

  1. Review results and destroy any remaining inventory of affected lots
  2. Affected lots should not be used for any clinical laboratory testing
  3. Complete and return the acknowledgement form for replacement or credit to be processed

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Class 2 Device Recall Oxoid Agglutinating Sera, Salmonella 90

- Databases

| |

| 510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards |

| CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | |

| New Search | ) |

| | Class 2 Device Recall Oxoid Agglutinating Sera, Salmonella 90 | |

Date Initiated by Firm March 25, 2026
Date Posted April 22, 2026
Recall Status Open , Classified
Recall Number Z-1923-2026
Recall Event ID 98652
Product Classification Antisera, all groups, salmonella spp. - Product Code GRM
Product Oxoid Agglutinating Sera, Salmonella 9-0
R30957301
Code Information UDI-DI 05056080500270
lots 6172600, 6172741, 6171393, 6150168, 6107767, 3766399, 3766400, 3780497, 3719592, 3709358, 6266130, 6253410, 6260215, 6222350, 6233859, 6233858
FEI Number 3003750284
Recalling Firm/
Manufacturer Remel Europe Ltd.

Clipper Boulevard West
Ken
Dartford United Kingdom |
| For Additional Information Contact | Erica Knox
800-2556730 |
| Manufacturer Reason
for Recall | Affected lots are not performing to IFU criteria showing cross reactions with 2-0 within 60 seconds. Cross-reactivity may result in the misidentification of a Salmonella 9-O serotype as a 2-O serotype. |
| FDA Determined
Cause | Under Investigation by firm |
| Action | Firm began notifying consignees on March 25, 2026 via letters titled "Urgent: Medical Device Recall."

Laboratory professionals are advised to review results and destroy any remaining inventory of affected lots. Affected lots should not be used for any clinical laboratory testing. Customers should complete and return the included acknowledgement form for replacement/credit to be processed. Notice should be passed on to all who need to be aware.

Firm is investigating the root cause and will implement corrective and preventive actions to prevent future recurrence. |
| Quantity in Commerce | 117 US; 950 OUS |
| Distribution | Worldwide - US Nationwide distribution to the states of AL, CA, FL, IA, IL, IN, MI, MN, MO, NC, NE, OH, SD, TX, WA. |
| Total Product Life Cycle | TPLC Device Report |

| 1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.

3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes. | |

Get daily alerts for FDA Device Recalls (Class II)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
March 25th, 2026
Instrument
Enforcement
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Healthcare providers Clinical investigators Medical device makers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Medical device recall response Diagnostic antisera testing Laboratory inventory quarantine
Geographic scope
United States US

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Product Safety Public Health

Get alerts for this source

We'll email you when FDA Device Recalls (Class II) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!